References
- Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–396.
- Wade JC, Schimpff SC, Newman KA, Weirnik PH. Staphylococcus epidermic/is: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982; 97: 503–508.
- Klastersky J. Concept of empiric therapy with antibiotic combinations. Am J Med 1986; 80, Suppl Sc: 2-12.
- Barnes RA, Rodgers TR. An evaluation of empirical antibiotic therapy in febrile neutropenic patients. Br J Haematol 1987; 66: 137–140.
- Kelsey SM, Weinhardt B, Collins PW, Newland AC. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 1992; 11: 509–514.
- European Organisation for Research and Treatment of Cancer International Antimicrobial Therapy Co-operative Group and National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951–958.
- ViSCOli C, Moroni C, Boni L et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric ther-apy in febrile neutropenic children with cancer. Rev Infect Dis 1991; 13: 397–404.
- Ramphal R, Bolger M, Oblon DJ et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomised prospective study. Antimicrob Agents Chemother 1992; 36: 1062-1067.
- Gold HS, Moellering JR. Antimicrobial drug resistance. N Engl J Med 1996; 335 (19): 1445–1453.
- Montecalvo MA, Shay DK, Patel P et al. Bloodstream infections with vancomycin resistant enterococci. Arch Intern Med 1996; 156 (13): 1458–1462.
- Gin AS, Zhanel GG. Vancomycin-resistant enterococci. Ann Pharmacother 1996; 30 (6): 615–624.
- Pizzo PA, Hathom JW, Hiemenz J et al. A randomised trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558.
- De Pauw BE, Deresinski SC, Field R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834–844.
- Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with cef-tazidime plus amikacin as empiric therapy for fever in granu-locytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108–1115.
- Wexler HM, Molitoris E, Finegold SM. Effect of 0-lac-tamase inhibitors on the activities of various 3-lactam agents against anaerobic bacteria. Antimicrob Agents Chemother 1991, 35: 1219-1224.
- Kelsey SM, Weinhardt B, Pocock CE, Shaw E, Newland AC. Piperacillin-tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy. J Chemother 1992; 4 (5): 281–285.
- Stefani S, Castiglia P, Maida A, Muresu E, Mezzatesta ML, Nicoletti G. Comparitive in-vitro activity of piperacillin and piperacillin plus tazobactam towards 3-lactam agents against anaerobic bacteria. J Chemother 1990; 2: 295–299.
- Cometta A, Zinner S, De Bock R et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39 (2): 445–452.
- Immunocompromised Host Society. The design, analy-sis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397–401.
- Holoszyc HM. An economical automated antibiotic disk-MIC testing system. Am Clin Lab 1996, 4: 15–17.
- Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal? Scand J Infect Dis 1995; (Suppl 96): 34-37.
- Leyland MJ, Bayston KF, Cohen J et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30: 843–854.
- The Meropenem Study Group. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1992, 36: 185–200.